CONTERA PHARMA A/S
CVR 33062214 · Public limited company (A/S) · Active · Low risk
CONTERA PHARMA A/S is a Public limited company (A/S), founded on , based in Hørsholm. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 0.1% over the next 12 months, which is 0.1 times the average for Danish companies. 16 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 79.5m and a net result of DKK -4.8m.
Bankruptcy risk for CONTERA PHARMA A/S
0.1 × the average (1.41%) · higher risk than 38% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 33062214
- Status
- Active
- Company type
- Public limited company (A/S)
- Founded
- (16 years)
- Address
- Venlighedsvej 4
2970 Hørsholm - Municipality
- Rudersdal
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 4.2m
- Employees
- 1 (2018)
- Auditor
- PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 16 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 81.5% |
| Current ratio | 501% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 1 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 8 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK 20.6m | DKK -54.1m |
| Net profit | DKK -4.8m | DKK -69.2m |
| Equity | DKK 79.5m | DKK 54.4m |
| Total assets | DKK 97.6m | DKK 63.6m |
| Cash | DKK 84.4m | – |
| Short-term debt | DKK 18.1m | – |
| Avg. employees | 14 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · PKF Munkebo Eriksen Funch, Statsautoriseret Revisions aktie selskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 105 | ||
| 1 Jan 2024 – 31 Dec 2024 | 139 | ||
| 1 Jan 2023 – 31 Dec 2023 | 135 | ||
| 1 Jan 2022 – 31 Dec 2022 | 114 | ||
| 1 Jan 2021 – 31 Dec 2021 | 167 | ||
| 1 Jan 2020 – 31 Dec 2020 | 85 | ||
| 1 Jan 2019 – 31 Dec 2019 | 143 | ||
| 1 Jan 2018 – 31 Dec 2018 | 162 | ||
| 1 Jan 2017 – 31 Dec 2017 | 170 | ||
| 1 Jan 2016 – 31 Dec 2016 | 139 | ||
| 1 Jan 2015 – 31 Dec 2015 | 111 | ||
| 1 Jan 2014 – 31 Dec 2014 | 152 | ||
| 1 Jan 2013 – 31 Dec 2013 | 143 | ||
| 1 Jan 2012 – 31 Dec 2012 | 154 | ||
| 1 Jan 2011 – 31 Dec 2011 | 159 | ||
| 9 Jul 2010 – 31 Dec 2010 | 160 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Mikael Søndergaard Thomsen | ||
| Board | Thomas Nikolaj Sager | Current | |
| Board | Paul Ejnar Gremaud Kristjansen | Current | |
| Board | Jee Hun Kim | Current | |
| Board | Jae Young Lee | Current | |
| Board | John Bondo Hansen | ||
| Board | Mikael Søndergaard Thomsen | ||
| Board | Frank Knudsen | ||
| Board | Bobby G Soni | ||
| Board | Carsten Schou | ||
| Board | Gunnar Magnus Severus Modee Persson | ||
| Board | Else Sissel Vorstrup | ||
| Board | Joseph Donald deBethizy | ||
| Board | Sang Hoon Kim | ||
| Board | Hee Won Yoo | ||
| Board | Jung Yoon Um | ||
| Board | Eun Ju Kim | ||
| Board | Sun Ho Kim | ||
| Board | Sung Joon Kim | ||
| Board | WooHyun Lee | ||
| Board | Jae Young Lee | ||
| Board | WooHyun Lee | ||
| Board | Mahmoud Mahmoudian | ||
| Board | Soo Yeon Park | ||
| Board | Mi Chung Ahn | ||
| Board | Mi Chung Ahn | ||
| Owner (90%) | Bukwang Pharmaceutical Co., Ltd | Current | |
| Owner (100%) | Bukwang Pharmaceutical Co., Ltd | ||
| Owner (67%) | Bukwang Pharmaceutical Co., Ltd | ||
| Owner (67%) | Bukwang Pharmaceutical Co., Ltd | ||
| Owner (25%) | Medici 2020-1 Private Equity Fund | ||
| Auditor | PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab | Current | |
| Auditor | PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab | ||
| Auditor | EY Godkendt Revisionspartnerselskab | ||
| Founder | CONCIT PHARMA HOLDING ApS | Current |
The CEOs' other companies
Mikael Søndergaard Thomsen – 7 other companies
- AmDen Pharmaceuticals Denmark ApS Active
- CONCIT PHARMA HOLDING ApS Opløst
- CONRIG PHARMA ApS Active
- Kariya Pharmaceuticals ApS Active
- MIKAEL SØNDERGÅRD THOMSEN ApS Active
- Ousia Pharma ApS Active
- SOUND BIOTECH ApS Opløst
Address history (4 moves)
| Venlighedsvej 4, 2970 Hørsholm | |
| Agern Alle 24, 2970 Hørsholm | |
| Ole Maaløes Vej 3, 2200 København N | |
| Kvæsthusgade 5C, 4., 1251 København K | |
| c/o John Bondo Hansen, Langåsen 3, 4450 Jyderup |
Former names
| CONTERA PHARMA A/S | – now |
| CONTERA PHARMA ApS | – |
| CONCIT PHARMA ApS | – |
Employees per year
Other companies at the same address
- CUTISENSE A/S Opløst
- DELTA CARE A/S Opløst
- DELTA NEW-BIZZ A/S Opløst
- DELTA READER A/S Opløst
- DRALLE A/S Active
- ICTALCARE A/S Active
- Presto Engineering Denmark ApS Active
- Threepoint Therapeutics ApS Active
Similar companies in Rudersdal
- Threepoint Therapeutics ApS Hørsholm
- Zaphe ApS Hørsholm
- Floratinia ApS Holte
- Dirac Drives ApS Hørsholm
- Johnsen Bioconsult ApS Skodsborg
- Dantefusion ApS Birkerød
- Typo foods ApS Vedbæk
- Pexinno ApS Holte
- Cerdes Science ApS Birkerød
- Pedersen Scientific ApS Birkerød
- NaviSurg Vision ApS Holte
- Fluispotter ApS Vedbæk
Questions and answers about CONTERA PHARMA A/S
Has CONTERA PHARMA A/S gone bankrupt?
No, CONTERA PHARMA A/S is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of CONTERA PHARMA A/S?
Our model estimates a bankruptcy risk of 0.1% over the next 12 months (low risk), which is 0.1 times the average for Danish companies.
Who is the auditor of CONTERA PHARMA A/S?
CONTERA PHARMA A/S most recently used PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab.
When was CONTERA PHARMA A/S founded?
CONTERA PHARMA A/S was founded on 9 July 2010.
What is the equity of CONTERA PHARMA A/S?
Equity was DKK 79.5m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.